According to the Zhitong Finance App, Hanson Pharmaceuticals (03692) announced interim results for the six months ended June 30, 2026. The group obtained revenue of RMB 8.304 billion (same unit), an increase of 11.71%; profit attributable to owners of the parent company was RMB 4.258 billion, an increase of 35.82% over the previous year; profit per share was 0.7 yuan, and an interim dividend of HK28.5 cents per share was planned.

According to the announcement, the increase in profit and basic earnings per share during the reporting period was mainly due to the combined effects of increased revenue from innovative drugs and other revenue increases.

In the six months ending June 30, 2026, the Group is conducting more than 70 innovative drug clinical trials, which are divided into more than 40 candidate innovative drugs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.